M-Prednisolone Indications/Uses

Endocrine disorders: primary or secondary adrenocortical insufficiency (in conjunction with mineralocorticoids, where applicable); acute adrenocortical insufficiency (mineralocorticoid supplementation may be necessary); shock secondary to adrenocortical insufficiency, or shock unresponsive to conventional therapy when adrenocortical insufficiency may be present (when mineralocorticoid activity is undesirable); preoperatively or in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful; congenital adrenal hyperplasia; non-suppurative thyroiditis; hypercalcemia associated with cancer.
Rheumatic disorders (as adjunctive therapy for short-term administration in the management of an acute episode or exacerbation): posttraumatic osteoarthritis; synovitis of osteoarthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis; acute and subacute bursitis; epicondylitis; acute nonspecific tenosynovitis; acute gouty arthritis; psoriatic arthritis; ankylosing spondylitis.
Collagen diseases and immune complex diseases (during an exacerbation or as maintenance therapy in selected cases): systemic lupus erythematosus; acute rheumatic carditis; systemic dermatomyositis (polymyositis).
Dermatologic disease: pemphigus; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative dermatitis; severe psoriasis; bullous dermatitis herpetiformis; severe seborrheic dermatitis; mycosis fungoides.
Allergic states (to control severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment): bronchial asthma; contact dermatitis; atopic dermatitis; serum sickness; seasonal or perennial allergic rhinitis; drug hypersensitivity reactions; urticarial transfusion reaction; acute noninfectious laryngeal edema.
Ophthalmic diseases (severe acute and chronic allergic and inflammatory processes involving the eye): herpes-zoster ophthalmicus; iritis, iridocyclitis; chorioretinitis; diffuse posterior uveitis and choroiditis; optic neuritis; sympathetic ophthalmia; anterior segment inflammation; allergic conjunctivitis; allergic corneal marginal ulcers; keratitis.
Gastrointestinal diseases (to manage critical period of the disease): ulcerative colitis; regional enteritis.
Respiratory disease: Symptomatic sarcoidosis; berylliosis; fulminating or disseminated tuberculosis (when used concurrently with appropriate antituberculous chemotherapy); Loeffler's syndrome not manageable by other means; aspiration pneumonitis; moderate to severe Pneumocystis jiroveci pneumonia in AIDS patients (as adjunctive therapy when given within the first 72 hours of initial anti-pneumocystis treatment).
Hematologic disorders: acquired (autoimmune) hemolytic anemia; idiopathic thrombocytopenic purpura in adult; secondary thrombocytopenia in adults; erythroblastopenia (RBC anemia); congenital (erythroid) hypoplastic anemia.
Neoplastic diseases (palliative management): leukemias and lymphomas in adults; acute leukemia of childhood.
Edematous states: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia.
Nervous System: acute exacerbations of multiple sclerosis.
Other indications: tuberculous meningitis with subarachnoid block or impending block (when used concurrently with appropriate chemotherapy); trichinosis with neurologic or myocardial involvement.